| 摘要 |
The present invention relates to a pharmaceutical combination, such as a combined preparation or pharmaceutical composition, respectively, comprising at least one DGAT1 inhibitor, or a pharmaceutically acceptable salt or ester thereof, at least one kind of triglyceride lowering drug selected from the group consisting of (a) at least one PPAR alpha agonist or a pharmaceutically acceptable salt thereof or ester thereof, and (b) at least one compound selected from the group consisting of (i) natural or synthetic omega-3 fatty acids or pharmaceutical acceptable esters, derivatives, conjugates, precursors or salts thereof or mixtures thereof, or (ii) omega-3 oils, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of hypertriglyceridemia, in particular chylomicronemia (also called hyperchylomicronemia); a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of hypertriglyceridemia, in particular chylomicronemia (also called hyperchylomicronemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. |
